Sorry, you need to enable JavaScript to visit this website.

PE: Managing Risk for Recurrent PE | XARELTO® (rivaroxaban)

Managing ongoing risk for recurrent PE

If you’ve completed at least 6 months of treatment for a pulmonary embolism (PE), it’s important to understand that certain risk factors—primarily ones that you can’t change or control—may mean you have an ongoing risk for recurrent PE. See why it’s important to help protect yourself against recurrent PE, and how XARELTO® may be able to help.

What are the PE risk factors that can contribute to multiple PEs?

  • A previous PE or deep vein thrombosis (DVT)
  • Having certain blood disorders that make your blood more likely to clot (eg, factor V Leiden, a mutation of one of the clotting factors involved in normal blood clotting)
  • Older age

If you stop taking a blood thinner:

After 5 years,
chance of another

After 10 years,
chance of another

Up to
of future PE or DVT
blood clots result in a
fatal PE

How do I know if I’m at risk for recurrent PE?

Your healthcare professional will evaluate your risk factors and may recommend that you continue taking a blood thinner like XARELTO®. This is important because some people who have had a PE or DVT and stop taking blood thinners have an even higher chance of having another blood clot.

How does a PE occur?

Click or tap on a number, or one of the arrows, to learn more about how blood clots can cause a PE.

left arrow desktopInfographic showing how the cardiovascular system worksRight arrow desktop

How can XARELTO® help?

Some people may be prescribed aspirin to help prevent them from having another PE. However, in a clinical trial with at-risk people who had already completed at least 6 months of initial treatment for a PE, XARELTO® was shown to be superior to aspirin at reducing their risk for future PEs.

  • The risk of another PE happening again was significantly lower with XARELTO® 10 mg than with aspirin*
  • Less than 1% of patients taking XARELTO® experienced major bleeding, which is similar to the rate of major bleeding in patients taking aspirin to reduce their risk of recurrent DVT or PE*

*After completion of initial treatment lasting at least 6 months.

Tiffany Video Thumbnail

Real people. Real stories.

Hear what XARELTO® has done for Tiffany.